Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy
| Autor: | Harry VanDusen, Amir T. Fathi, Gabriela S. Hobbs, Julia Foster, Areej El-Jawahri, Daniel J. DeAngelo, David P. Steensma, Jennifer S. Temel, Thomas W. LeBlanc, Nora Horick, Martha Wadleigh, Lauren Waldman, Richard Stone, Gregory A. Abel, Philip C. Amrein, Joseph A. Greer, Lara Traeger, Netana Markovitz, Andrew M. Brunner |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_specialty Longitudinal study Anthracycline medicine.medical_treatment Antineoplastic Agents Anxiety 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine medicine Humans Anthracyclines Longitudinal Studies Depression (differential diagnoses) Aged Aged 80 and over Chemotherapy Depression business.industry Cytarabine Hematology Middle Aged Affect Leukemia Myeloid Acute 030104 developmental biology Mood Oncology 030220 oncology & carcinogenesis Quality of Life Female medicine.symptom business medicine.drug |
| Zdroj: | Leukemia. 33:2393-2402 |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | Older patients with AML face difficult treatment decisions as they can be treated either with ‘intensive’ chemotherapy requiring prolonged hospitalization, or ‘non-intensive’ chemotherapy. Although clinicians often perceive intensive chemotherapy as more burdensome, research is lacking on patients’ quality of life (QOL) and psychological distress. We conducted a longitudinal study of older patients (≥60 years) newly diagnosed with AML receiving intensive (cytarabine/anthracycline combination) or non-intensive (hypomethylating agents) chemotherapy. We assessed patients’ QOL [Functional-Assessment-of-Cancer-Therapy-Leukemia] and psychological distress [Hospital-Anxiety-and-Depression-Scale] at baseline and 2, 4, 8, 12, and 24 weeks after diagnosis. We enrolled 75.2% (100/133) of eligible patients within 72-hours of initiating intensive (n = 50) or non-intensive (n = 50) chemotherapy. Patient QOL improved over time (β = 0.32, P = 0.013). At baseline, 33.3% (33/100) and 30.0% (30/100) of patients reported clinically significant depression and anxiety symptoms, respectively, with no differences between groups. Patients’ depression symptoms did not change over time, while their anxiety symptoms decreased over time (β = −0.08, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink